|
||||
Congratulations to Christie Aschwanden, one of this year’s winners of the Science in Society Journalism Awards, sponsored by the National Association of Science Writers. Her piece, “The Real Scandal: Science Denialism at Susan G. Komen for the Cure” was posted on February 8, 2012, on the web site The Last Word on Nothing. “It asserts that Susan G. Komen for . . . → Read More: Congratulations to Christie Aschwanden, 2013 Science in Society Journalism Awards 
She is the protagonist of the epic breast cancer survivor story. She exists in many iterations; in magazines, advertisements, news stories, and awareness events. She is a superwoman who courageously, passionately, and aggressively battles disease. She faces tremendous difficulties. With style and optimism, she learns from her experience, is transformed, and shares lessons learned. She is the SHE-RO, the triumphant . . . → Read More: The She-ro 
Dr. Susan Love just announced that three breast cancer organizations have joined forces to document the short- and long-term physical and emotional side effects of breast cancer treatments. The collaboration is part of the Dr. Susan Love Research Foundation’s Health of Women [HOW] Study. The goal is to collect data on the collateral damage of breast cancer treatments to share . . . → Read More: Dr. Susan Love Research Foundation Teams with Susan G. Komen and Young Survival Coalition to Document the Collateral Damage of Breast Cancer 
Seth Godin defines a brand as “the set of expectations, memories, stories and relationships that, taken together, account for a consumer’s decision to choose one product or service over another. If the consumer (whether it’s a business, a buyer, a voter or a donor) doesn’t pay a premium, make a selection or spread the word, then no brand value exists . . . → Read More: Breast Cancer, Concept Brand with Pink Ribbon Logo 
The Changing Breast Cancer Landscape The past three months have seen significant changes not only in the breast cancer arena but in science and medicine more generally. Barbara Brenner, one of my personal she-roes, who led the group Breast Cancer Action, died on May 10 at her home in San Francisco. She was 61. Angelina Jolie surprised the public with . . . → Read More: BCC Newsletter (2013, Issue 3) 
I was taken aback a moment ago when I came across a Facebook update from yesterday posted by a Komen Affiliate. It was advertising free mammograms. There is nothing wrong with offering free mammograms per se, but the announcement included a heavily scrutinized advertisement that claims getting screened is the key to surviving breast cancer. It isn’t. If concern about . . . → Read More: Komen, Still Spreading Screening Hype 
As part of a National Cancer Institute working group, Dr. Laura J. Esserman MD, MBA of Mt Zion Carol Franc Buck Breast Cancer Center along with colleagues Ian Thompson MD of the University of Texas Health Science Center at San Antonio and Brian Reid MD, PhD of Fred Hutchinson Cancer Research Center in Seattle, Washington, wrote an article in the . . . → Read More: “Carcinoma”: What’s in a name? 
The Telegraph recently reported that, “More than 500,000 women at risk of breast cancer because of their family history should take tamoxifen as preventive measure.” The story is based on a new set of guidelines from the National Institute for Health and Care Excellence in the UK recommending chemoprevention drugs to women who have not been diagnosed with breast cancer . . . → Read More: Chemoprevention Is No Magic Bullet 
A group of more than 100 experts from more than 15 countries wrote an editorial in the medical journal Blood, to call attention to the impact of exorbitant drug prices on patients. Focusing on their area of expertise in chronic myeloid leukemia (CML) — a rare form of cancer affecting white blood cells – the authors consider why some patients . . . → Read More: Life-saving drugs, lethal prices 
(CNN) — Angelina Jolie, when writing about her preventive double mastectomy, did not discuss how much her surgeries cost, but she did mention that many women would not be able to afford the $3,000 to $4,000 test that led her to make the decision. What she failed to say was why the test costs so much. The reason is this: . . . → Read More: Why Jolie’s cancer test costs so much |
"women urged to get screened because it might save their lives. But that’s only 1 possible outcome, and it’s the least likely one" @cragcrest cutt.ly/jei8WJr 
 |
|||
| Copyright © Gayle Sulik 2025 Pink Ribbon Blues - All Rights Reserved - Images on this site are used for the express purposes of commentary and criticism under the fair use doctrine. | ||||
